Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
J Bone Miner Metab ; 40(4): 704-711, 2022 Jul.
Article in English | MEDLINE | ID: mdl-35637395

ABSTRACT

INTRODUCTION: Prostate cancer often forms osteoblastic lesions that appear as a high-dense shadow upon X-ray. Although the lesions may seem to increase bone strength, pathological fracture occurs in one in four patients with prostate cancer. The aim of this study is to elucidate the factors that may increase the risk of pathological fracture in patients with prostate cancer metastases in the proximal femur by analyzing computed tomography data. MATERIALS AND METHODS: Computed tomography data of the femur of 62 prostate cancer patients were retrospectively analyzed. The patients were divided into three groups based on the presence or absence of femoral metastatic lesions and pathological fracture. Surgical specimens of the proximal femur collected from patients who had a pathological fracture were histologically analyzed. RESULTS: Bone density in the marrow area was increased in all cases with metastases compared with those with no metastases. Contrarily, the cortical bone density at the medial trochanter region was significantly lower in patients who had pathological fractures in the proximal femur than those who did not. Accordingly, histological analysis of the surgical specimens revealed that the affected cortical bone was osteopenic without any apparent new bone formation. CONCLUSION: These results indicate that prostate cancer is less effective in inducing bone formation in the cortex than in the marrow and that the decrease in the cortical bone density at the medial trochanter region leads to an increased risk of pathological fracture. Therefore, a previously undocumented risk factor for pathological fracture in prostate cancer patients is presented.


Subject(s)
Femoral Fractures , Fractures, Spontaneous , Prostatic Neoplasms , Bone Density , Femoral Fractures/diagnostic imaging , Femoral Fractures/pathology , Femur/diagnostic imaging , Femur/pathology , Fractures, Spontaneous/complications , Fractures, Spontaneous/pathology , Humans , Male , Prostatic Neoplasms/complications , Retrospective Studies , Risk Assessment , Tomography, X-Ray Computed/methods
2.
Biochem Biophys Res Commun ; 570: 89-95, 2021 09 17.
Article in English | MEDLINE | ID: mdl-34274851

ABSTRACT

Eribulin is a novel microtubule inhibitor that, similar to other types of microtubule inhibitors, induces apoptosis by inhibiting the mitotic division of cells. Besides this direct effect on tumor cells, previous studies have shown that eribulin has the potential to induce tumor vascular remodeling in several different cancers; however, the mechanisms underlying this phenomenon remain unclear. In the present study, we aimed to elucidate whether eribulin is effective against synovial sarcoma, a relatively rare sarcoma that often affects adolescents and young adults, and to histologically investigate the microstructure of tumor vessels after the administration of eribulin. We found that eribulin exhibits potent antitumor activity against synovial sarcoma in a tumor xenograft model and that tumor vessels frequently have intervascular pillars, a hallmark of intussusceptive angiogenesis (IA), after the administration of eribulin. IA is a distinct form of angiogenesis that is involved in normal developmental processes as well as pathological conditions. Our data indicate that IA is potentially involved in eribulin-induced vascular remodeling and thereby suggest previously unacknowledged role of IA in regulating the tumor vasculature after eribulin administration.


Subject(s)
Furans/therapeutic use , Intussusception/complications , Ketones/therapeutic use , Neovascularization, Pathologic/drug therapy , Sarcoma/blood supply , Sarcoma/drug therapy , Vascular Remodeling , Animals , Bevacizumab/pharmacology , Bevacizumab/therapeutic use , Cell Line, Tumor , Cell Proliferation/drug effects , Cell Shape/drug effects , Endothelial Cells/drug effects , Endothelial Cells/ultrastructure , Furans/administration & dosage , Furans/pharmacology , Intussusception/drug therapy , Ketones/administration & dosage , Ketones/pharmacology , Mice, Inbred BALB C , Mice, Nude , Neovascularization, Pathologic/complications , Pericytes/drug effects , Pericytes/pathology , Pericytes/ultrastructure , Sarcoma/complications , Sarcoma/ultrastructure , Tumor Hypoxia/drug effects , Vascular Endothelial Growth Factor A/metabolism , Vascular Remodeling/drug effects , Xenograft Model Antitumor Assays
4.
Bone Rep ; 18: 101693, 2023 Jun.
Article in English | MEDLINE | ID: mdl-37305428

ABSTRACT

Over the past few decades, the clinical outcomes of patients with cancer have significantly improved mostly owing to the development of effective chemotherapeutic treatments. However, chronic health conditions such as bone mass loss and risk of fragility fractures caused by chemotherapy have also emerged as crucial issues in patients treated for cancer. In this study, we aimed to understand the effect of eribulin mesylate (ERI), a microtubule-targeting agent currently used to treat metastatic breast cancer and certain subtypes of advanced sarcomas, on bone metabolism in mice. The administration of ERI reduced bone mass in mice, mainly by promoting osteoclast activity. Gene expression analysis of skeletal tissues revealed no change in the expression levels of the transcripts for RANK ligand, one of the master regulators of osteoclastogenesis; however, the transcript levels of osteoprotegerin, which neutralizes RANK ligand, were significantly reduced in ERI-treated mice compared with those in vehicle-treated controls, indicating a relative increase in RANK ligand availability after ERI treatment. In line with the increased bone resorption in ERI-treated mice, we found that zoledronate administration effectively suppressed bone loss in these mice. These results reveal a previously unrecognized effect of ERI on bone metabolism and suggest the application of bisphosphonates for patients with cancer undergoing treatment with ERI.

5.
J Orthop Res ; 40(4): 945-953, 2022 04.
Article in English | MEDLINE | ID: mdl-34057747

ABSTRACT

Osteosarcoma (OS) is the most common primary bone tumor that mainly affects adolescents and young adults. Although standard treatment modality can achieve up to 60%-70% 5-year survival rate, there has not been any substantial improvement over the past four decades. Furthermore, those presenting with pulmonary metastatic lesions often undergo a highly unfavorable clinical course. Therefore, there is a severely unmet clinical need to provide a more effective treatment for patients with OS. In this study, we show that trabectedin (TBD), a chemotherapeutic agent approved for soft tissue sarcomas, significantly suppresses pulmonary metastasis in a mouse OS xenograft model. In vitro experiments revealed that TBD suppresses cell migration potentially by downregulating the activity of ERK1/2, intracellular molecules that are critically involved in the regulation of cell motility. Collectively, our data may provide a basis for further investigation of TBD on the potential use for OS patients who are at great risk of pulmonary metastasis.


Subject(s)
Bone Neoplasms , Lung Neoplasms , Osteosarcoma , Adolescent , Animals , Bone Neoplasms/drug therapy , Bone Neoplasms/pathology , Cell Line, Tumor , Cell Movement , Cell Proliferation , Disease Models, Animal , Heterografts , Humans , Lung Neoplasms/pathology , Mice , Neoplasm Metastasis , Osteosarcoma/drug therapy , Osteosarcoma/pathology , Trabectedin/therapeutic use
6.
JBJS Case Connect ; 6(2): e24, 2016 Apr 13.
Article in English | MEDLINE | ID: mdl-29252618

ABSTRACT

CASE: We present an extremely rare case of an avulsion fracture of the medial head of the gastrocnemius muscle associated with posterior dislocation of the knee. The patient was a fifty-one-year-old man who was hit by a car while riding a motorcycle. The avulsed fragment was reduced and fixed with a screw, which resulted in maintenance of joint reduction despite residual instability due to the multiligamentous injuries. CONCLUSION: Reduction and fixation of the bone fragment attached to the medial head of the gastrocnemius muscle is important to restore tension of the gastrocnemius muscle, which serves as an important posterior joint stabilizer.

SELECTION OF CITATIONS
SEARCH DETAIL